LON:VRP - Verona Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 73 +5.50 (+8.15 %) (As of 01/17/2019 09:41 AM ET)Previous CloseGBX 67.50Today's RangeGBX 66.63 - GBX 7352-Week RangeGBX 100 - GBX 189Volume10,742 shsAverage Volume49,797 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. Receive VRP News and Ratings via Email Sign-up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:VRP Previous Symbol CUSIPN/A Webwww.veronapharma.com Phone+44-20-32834200Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding SharesN/AMarket Cap£0.00 OptionableOptionable Verona Pharma (LON:VRP) Frequently Asked Questions What is Verona Pharma's stock symbol? Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP." How were Verona Pharma's earnings last quarter? Verona Pharma Plc (LON:VRP) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($14.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($23.70) by $9.20. View Verona Pharma's Earnings History. What price target have analysts set for VRP? 3 brokers have issued twelve-month price targets for Verona Pharma's stock. Their forecasts range from GBX 160 to GBX 348. On average, they anticipate Verona Pharma's share price to reach GBX 254 in the next year. This suggests a possible upside of 247.9% from the stock's current price. View Analyst Price Targets for Verona Pharma. What is the consensus analysts' recommendation for Verona Pharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verona Pharma. Has Verona Pharma been receiving favorable news coverage? Headlines about VRP stock have trended somewhat negative on Thursday, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verona Pharma earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Verona Pharma's key competitors? Some companies that are related to Verona Pharma include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB). Who are Verona Pharma's key executives? Verona Pharma's management team includes the folowing people: Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 63)Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)Ms. Claire Louise Poll B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 51)Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 56)Mr. Richard Hennings, Commercial Director (Age 48) How do I buy shares of Verona Pharma? Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Verona Pharma's stock price today? One share of VRP stock can currently be purchased for approximately GBX 73. What is Verona Pharma's official website? The official website for Verona Pharma is http://www.veronapharma.com/. How can I contact Verona Pharma? Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200. MarketBeat Community Rating for Verona Pharma (LON VRP)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 163 (Vote Outperform)Underperform Votes: 177 (Vote Underperform)Total Votes: 340MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: What are Institutional Investors?